Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Up 118.4% in May

Liminatus Pharma Inc. (NASDAQ:LIMN) was the recipient of a large growth in short interest in May. As of May 29th, there was short interest totaling 1,228,229 shares, a growth of 118.4% from the May 14th total of 562,363 shares. Based on an average trading volume of 44,575,019 shares, the days-to-cover ratio is presently 0.0 days. Currently, 2.7% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Liminatus Pharma in a research report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Liminatus Pharma Stock Performance

Shares of Liminatus Pharma stock opened at $0.12 on Friday. Liminatus Pharma has a 1 year low of $0.12 and a 1 year high of $33.66. The company has a market capitalization of $5.48 million and a P/E ratio of -0.28. The company’s fifty day moving average is $0.18 and its two-hundred day moving average is $0.47.

Liminatus Pharma (NASDAQ:LIMN) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.03) earnings per share (EPS) for the quarter.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.